Close Menu
Home » Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

Jun 19, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Invivoscribe announced today that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the firm's LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo's quizartinib for the treatment of FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep Them or Not?

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

Dunno Whose It Is

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

Knowing Risk From a Young Age

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

Science Translational Medicine Paper Finds Drug Combo Boosts KRAS Inhibitor Efficacy in Lung Cancer

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In PCR

  1. Roche Gains FDA Clearance for Cobas Babesia Blood Test

  2. Curetis Reports 36 Percent Increase in H1 Revenues

  3. PredictImmune Expands Licensing Deal With Cambridge Enterprise

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.